MedTrace Logo

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

NCT05497284 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-01-13

Study results available
· View outcomes & findings →

Summary

A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis

Conditions

Interventions

DRUG

LTP001

LTP001 administered once daily in the morning

DRUG

Placebo

Placebo to LTP001 administered once daily in the morning

DRUG

Standard of Care (SoC)

nintedanib, pirfenidone, or neither

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-10
Primary Completion
2024-08-26
Completion
2024-09-26
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Czechia
  • Germany
  • Netherlands
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05497284 on ClinicalTrials.gov